{"slug": "newlimit-says-its-ai-system-reversed-aging-signs-in-human-liver-cells", "title": "NewLimit Says Its AI System Reversed Aging Signs in Human Liver Cells", "summary": "NewLimit, a San Francisco longevity biotech co-founded by Coinbase CEO Brian Armstrong, reported that its AI system Ambrosia reversed aging signs in human liver cells from donors over 60, and closed a $435 million Series C in June led by Founders Fund at a $3.1 billion valuation. The company's first clinical trial is not scheduled until 2027, and the data has not been peer-reviewed.", "body_md": "*NewLimit says an AI system it calls Ambrosia found a way to make old human liver cells behave like young ones again, and in June investors backed that claim with $435 million.*\n\nBrian Armstrong built his fortune arguing that software could replace banks. His newest bet is that software can also talk a 60-year-old liver cell into acting 20 again. The Coinbase co-founder and CEO backs NewLimit, a San Francisco longevity biotech he helped start in 2021 with former GV partner Blake Byers and computational biologist Jacob Kimmel, who now runs the company as CEO. In January, according to a company update posted on NewLimit's blog, a reprogrammed liver cell taken from a donor over 60 started expressing genes associated with cells decades younger. Its resilience to alcohol damage went up. Its regenerative capacity improved.\n\nThat's the headline claim. Here's the number that made Wall Street pay attention: $435 million. NewLimit closed a Series C in June led by Founders Fund, according to STAT News, pushing its valuation to $3.1 billion. Less than a year earlier the company was worth under $1 billion. That's more than a threefold jump on the strength of cell data, not a marketed drug.\n\nAmbrosia is what NewLimit calls a \"lab-in-the-loop\" system. It doesn't just crunch existing data. It proposes experiments, reads back the results, and proposes the next round. In its work on the liver, the system tested more than 3,000 combinations of transcription factors, the proteins that switch genes on and off, and screened over 50 candidate treatments before narrowing in on a handful that made aged hepatocytes look young again by four separate biomarkers. That's the scale of the search. In follow-up mouse studies using diet-induced liver injury models, two of those candidates cut circulating markers of liver damage, the company says. In February, Kimmel described a related result: old mice dosed with alcohol showed less liver damage after treatment, a finding one outlet summed up as reversing hangovers in old mice. It's a memorable way to put it. And it's also the kind of specific, checkable detail most AI longevity press releases don't bother to include.\n\n## The Gap Between the Lab and Medicine\n\nNone of this has been through peer review. It's company-reported data from company-run experiments, which is a very different thing from a published, independently replicated study. NewLimit hasn't dosed a single human being. Its first clinical trial, targeting liver disease, isn't scheduled to start until 2027. Frankly, that's the gap between \"reversed aging\" as a press release and \"reversed aging\" as medicine, and it's a wide one. Plenty of biotech claims that looked stunning in a dish or a mouse model died the moment they hit a clinical trial.\n\n[Giving Your AI Agent an Email Address Is Now a Real Product Category](https://startupfortune.com/giving-your-ai-agent-an-email-address-is-now-a-real-product-category/)\n\nAI agents can send email easily, but receiving replies and holding a thread together is still the hard part. This piece compares seven email services and APIs, from AgentMail's newly funded inbox-first approach to Postmark, Resend, Mailgun, SendGrid, Amazon SES, and Mailtrap, on what actually works for autonomous agents. - [AI agents with email inbox functionality capabilities](https://startupfortune.com/giving-your-ai-agent-an-email-address-is-now-a-real-product-category/) - [email API platforms for autonomous agent communication workflows](https://startupfortune.com/giving-your-ai-agent-an-email-address-is-now-a-real-product-category/)\n\n## A Pattern Bigger Than One Liver Cell\n\nStill, the pattern matters beyond NewLimit. Insilico Medicine took its AI-designed lung disease drug, rentosertib, from target identification to a Phase III trial in under 30 months, a process that traditionally eats up six to eight years. Eli Lilly liked what it saw enough to sign a $2.75 billion deal with Insilico for age-related disease candidates. NewLimit's jump from a private valuation under $1 billion to $3.1 billion in less than a year tells you investors are pricing AI-driven biotech less like a slow-moving pharma bet and more like a software company that just shipped a breakthrough.\n\nYou don't need to believe aging is \"solved\" to see why that matters for founders and investors watching this space. The compressed timeline is the real story, not the specific liver cell. If an AI system can genuinely cut years off early-stage discovery and screening, the economics of longevity biotech change even before a single drug reaches the market. That's what's being priced into NewLimit's $3.1 billion valuation right now: a bet on the process, well ahead of any proof the medicine works in a human body.\n\nNewLimit's own scientists seem to know the difference between a lab result and a cure. The company's public materials describe this as early evidence, not a finished therapy, and the 2027 trial start date is the real test everyone should be watching, not the cell data from a lab in South San Francisco back in January.\n\n**Also read:** [Nvidia Is Buying the AI Startup That OpenAI's Own Models Hacked](https://startupfortune.com/nvidia-is-buying-the-ai-startup-that-openais-own-models-hacked/) • [Taiwan Turns Its Chip Dominance Into Diplomatic Leverage Over the US and EU](https://startupfortune.com/taiwan-turns-its-chip-dominance-into-diplomatic-leverage-over-the-us-and-eu/) • [Authors Fight Publishers And Agents Over Anthropic's $1.5 Billion Settlement](https://startupfortune.com/authors-fight-publishers-and-agents-over-anthropics-15-billion-settlement/)\n\n## Join the discussion\n\n[Open in the community →](/community/)\n\nAlmost there. Sign in and your reply posts straight away.", "url": "https://wpnews.pro/news/newlimit-says-its-ai-system-reversed-aging-signs-in-human-liver-cells", "canonical_source": "https://startupfortune.com/newlimit-says-its-ai-system-reversed-aging-signs-in-human-liver-cells/", "published_at": "2026-09-07 09:41:28+00:00", "updated_at": "2026-09-07 09:55:50.535955+00:00", "lang": "en", "topics": ["artificial-intelligence", "ai-research", "ai-startups"], "entities": ["NewLimit", "Brian Armstrong", "Coinbase", "Blake Byers", "Jacob Kimmel", "Founders Fund", "Ambrosia", "STAT News"], "alternates": {"html": "https://wpnews.pro/news/newlimit-says-its-ai-system-reversed-aging-signs-in-human-liver-cells", "markdown": "https://wpnews.pro/news/newlimit-says-its-ai-system-reversed-aging-signs-in-human-liver-cells.md", "text": "https://wpnews.pro/news/newlimit-says-its-ai-system-reversed-aging-signs-in-human-liver-cells.txt", "jsonld": "https://wpnews.pro/news/newlimit-says-its-ai-system-reversed-aging-signs-in-human-liver-cells.jsonld"}}